News and Announcements
Riccardo Canevari of Radiopharm Theranostics (ASX:RAD)
- Published December 06, 2022 6:49AM UTC
- Publisher Maan Perez
- Categories Executive Interviews
Radiopharm Theranostics (ASX:RAD) is a clinical stage radiotherapeutics company developing a world-class platform of innovative radiopharmaceutical products for diagnostic and therapeutic applications in areas of high unmet medical need. The company has a pipeline of four distinct and highly differentiated platform technologies spanning peptides, small molecules, and monoclonal antibodies for use in cancer, from some of the world’s leading universities and institutes.
Watch this interview with CEO Riccardo Canevari as he discusses how they approach oncology with their unique processes.
Executive Interviews
Why Are Fewer Companies Going Public?
The number of companies listing on the ASX has declined, driven by access to private capital, regulatory burdens, and market volatility. However, public markets still offer liquidity, visibility, and robust capital-raising opportunities.
A Message to Founders: A Shared Journey to 2025 – A Once in a Generation Opportunity
As we close this challenging year, let’s reflect on the resilience, lessons, and growth that brought us here. Founders, 2025 is your golden opportunity to innovate, scale, and thrive. Set your strategy, rest, and prepare to sprint into a year of unparalleled possibilities.
From Trash to Treasure: Inside Australia’s First Commercial Waste-to-Hydrogen Facility
Greenhill Energy’s pioneering waste-to-hydrogen facility marks a significant step in sustainable energy. This Australian innovation is transforming waste management into clean, valuable hydrogen, presenting investors with a unique, forward-thinking opportunity.
Backed By Leading Investment Groups and Family Offices
